Table 4.
The prevalence of different HPV type combinations in 6286 women, China, stratified by cytology n (%).
| Genotyping | Total * (n = 6185) |
NILM (n = 5309) |
ASCUS (n = 486) |
LSIL (n = 223) |
AGC (n = 20) |
HSIL (n = 134) |
Cancer (n = 13) |
ASCUS+ (n = 876) |
|---|---|---|---|---|---|---|---|---|
| HPV6/11 | 68 (1.1) | 49 (0.9) | 8 (1.6) | 9 (4.0) | 0 (0.0) | 1 (0.7) | 1 (7.7) | 19 (2.1) |
| 14 HR-HPV | 1193 (19.3) | 772 (14.5) | 125 (25.7) | 162 (72.6) | 8 (40.0) | 113 (84.3) | 13 (100.0) | 421 (48.1) |
| Other LR-HPV 26/40/43/44/53/54/69/70/71/73/74/82 | 418 (6.8) | 300 (5.7) | 44 (9.1) | 53 (23.8) | 1 (5.0) | 19 (14.2) | 1 (7.7) | 118 (13.5) |
| Vaccines approved by NMPA | ||||||||
| HPV16/18 | 342 (5.5) | 181 (3.4) | 33 (6.8) | 47 (21.1) | 2 (10.0) | 69 (51.5) | 10 (76.9) | 161 (18.4) |
| HPV6/11/16/18 | 405 (6.5) | 229 (4.3) | 41 (8.4) | 54 (24.2) | 2 (10.0) | 69 (51.5) | 10 (76.9) | 176 (20.1) |
| HPV6/11/16/18/31/33/45/52/58 | 867 (14.0) | 536 (10.1) | 102 (21.0) | 105 (47.1) | 7 (35.0) | 105 (78.4) | 12 (92.3) | 321 (36.6) |
| Vaccines in clinical trial # | ||||||||
| HPV16/18/58 ① | 461 (7.5) | 238 (4.5) | 54 (11.1) | 66 (29.6) | 4 (20.0) | 88 (65.7) | 11 (84.6) | 223 (25.5) |
| HPV16/18/52/58 ② | 681 (11.0) | 399 (7.5) | 80 (16.5) | 87 (39.0) | 5 (25.0) | 99 (73.9) | 11 (84.6) | 282 (32.2) |
| HPV6/11/16/18/31/33/45/52/58/59/68 ③ | 957 (15.5) | 607 (11.4) | 111 (22.8) | 113 (50.7) | 7 (35.0) | 107 (79.9) | 12 (92.3) | 350 (40.0) |
| HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59 ④ | 1125 (18.2) | 724 (13.6) | 121 (24.9) | 148 (66.4) | 8 (40.0) | 111 (82.8) | 13 (100.0) | 401 (45.8) |
* A total number of 6,286,101 dissatisfied cytology cases were excluded; negative for intraepithelial lesion or malignancy (NILM); atypical squamous cells of undetermined significance (ASCUS); atypical glandular cells (AGC); low-grade squamous intraepithelial lesions (LSIL); high-grade squamous intraepithelial lesions (HSIL); ASCUS or above(ASCUS+); National Medical Products Administration (NMPA). # The vaccines in clinical trial for the HPV types, which were the same as four Vaccines approved by NMPA, were excluded. ① The 3-valent vaccine from Health Guard Biological Technology Inc. (Hong Kong, China). ② The 4-valent vaccine from SL PHARM Inc. (Beijing, China). ③ The 11-valent vaccine from National Vaccine & Serum Institute (Beijing, China). ④ The 14-valent vaccine from Sinocelltech Ltd. (Beijing, China).